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Effect of Pharmacist-Led Medication Review on Medication Appropriateness in Older 
Adults with Chronic Kidney Disease 
Abstract 
This study evaluated the impact of pharmacist-led review on medication 
appropriateness in 204 older patients (aged ≥65 years) with chronic kidney disease (CKD) 
admitted to an Australian hospital. Medication appropriateness was evaluated using the 
Medication Appropriateness Index (MAI) prior to medication review, after review (assuming 
all recommendations were accepted by physicians) and after outcome (acceptance/non-
acceptance) of recommendations. 
Overall, 95 (46%) patients received a medication review by pharmacists. The median 
(interquartile range) MAI score significantly decreased from a baseline of 7 (3-12) to 5 (2-10) 
after medication review (p<0.001) and to 6 (2-10) after the outcome of recommendations 
(p<0.01). The MAI score also decreased from admission to discharge (6 [3-11] to 5 [2-9]; 
p<0.001) in patients with no medication review by a pharmacist. The MAI scores decline 
markedly in people with all the pharmacist-conducted medication review recommendations 
accepted (from 7 to 3; p<0.05). 
Reassuringly, hospitalisation alone improved medication appropriateness. However, 
pharmacist-led medication review can further optimise medication appropriateness in older 










Older adults with chronic kidney disease (CKD) are t increased risk of receiving inappropriate 
medications and experiencing adverse drug events.1, 2 Moreover, aging and advanced CKD are 
associated with multiple chronic conditions and the use of a higher number of medications,3,4 
which in turn is associated with patient morbidity and mortality.5 As such, measuring 
inappropriate medication use in older people is a research topic of significant interest. In line 
with this, various criteria, both implicit and explicit, have been developed in recent decades to 
assess the appropriateness of prescribing in older adults.6  
Implicit criteria are generally thought to give a more comprehensive and holistic assessment of 
pharmacotherapy, mainly because of the detailed clinical information used, compared to their 
explicit counterparts.7-9 The Medication Appropriateness Index (MAI) is one of the implicit 
measures used to evaluate medication appropriateness in older adults.  This tool detects 
potentially inappropriate prescribing more frequently than other explicit criteria, with 
acceptable validity and intra- and inter-rater reliability.10 The MAI has been used to assess the 
quality of prescribing in different health settings and was predictive of various health outcomes, 
including quality of life and medication-related hospitalisations.10,11 The MAI was also 
previously applied to evaluate the impact of medication review conducted by pharmacists on 
medication appropriateness.11-14 
In Australia, government-funded medication review services, in the form of home (HMRs) and 
residential medication management reviews (RMMRs), are important strategies to improve the 
appropriate use of medications.15 These programs require a coordinated effort among general 
practitioners, pharmacists, and patients to identify and correct medication issues. Similarly, the 
Society of Hospital Pharmacists of Australia has a standard of practice in place for pharmacists 
to be involved in clinical services in hospitals, to optimise patient outcomes by aiming to 
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improve the quality use of medications.16 It has been reported, however, that hospital 
pharmacists spend less than half of their time in providing clinical and drug information 
services.15 Ideally, every patient should receive clinical pharmacy services during 
hospitalisation, yet limited funding and inadequate staffing may limit implementation in 
inpatient settings.16 Therefore, pharmacists may need to prioritise the reviewing of patients 
based on their risk of medication-related problems.16 
The implementation of clinical pharmacy services has contributed to the improvement of 
patient outcomes.17,18 However, little is known about the impact of pharmacist-led medication 
review on the quality of prescribing in older adults with CKD. Therefore, we examined the 
impact of medication review by pharmacists during hospitalisation on medication 
appropriateness in older adults with CKD. We also identified the type of recommendations 
commonly given by pharmacists and the medications commonly implicated in medication-
related problems. 
Methods 
Study participants, setting and data collection 
This was a cross-sectional comparative study conducted retrospectively in a 500-bed 
Tasmanian tertiary care hospital. All older adults (aged ≥65 years) with CKD and not receiving 
any form of renal replacement therapy, who were consecutively admitted over a period of six 
months (January 2015 – June 2015), were included for analysis. For this study, CKD was 
defined based on an estimated glomerular filtration rate (eGFR) of 15-60 mL/min/1.73m2, 
reported via the CKD Epidemiology Collaboration (CKD-EPI) equation,19 present for at least 
three months.20 People with acute kidney injury, those who did not have repeated eGFR 
measures for at least three months, had stayed in hospital briefly (<24 hours), were critically 
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ill/ died during hospitalisation and those with incomplete medical records were excluded from 
the study.  
Comprehensive patient, medical and laboratory information, including both regular and ‘as 
needed’ medications, was collected from the digital medical record at hospital admission and 
discharge. Medications that were used for a short period, such as acutely used antibiotics and 
medications prescribed for in-hospital use, were excluded from the evaluation of medication 
appropriateness. Medical progress notes were thoroughly examined by the principal 
investigator (WHT) for pharmacists’ reviews and recommendations during hospitalisation.  
Medication appropriateness was evaluated using the MAI prior to medication review by 
pharmacists, after review (assuming all recommendations were accepted by physicians) and 
after the outcome of recommendations (i.e. acceptance or non-acceptance by physicians). This 
tool has ten components, assessing indication, effectiveness, dosageappropriateness, directions 
of use and their practicality, drug-drug and drug-disease interactions, expense, duplication of 
therapy and duration of treatment. Each criterion has special rating instructions, operational 
definitions, and referential guides to rate the degree of appropriateness.10 These criteria have 
weighted scores and the MAI score for an individual drug ranges between 0 and 18. Patient 
MAI scores are the sum of the scores of their individual medications, and higher scores are 
indicative of high level of medication inappropriateness.21 For the purpose of this study, after 
trialling the tool on 10 patients, the investigators agreed to remove two components: 
‘practicality of directions’ and ‘expense’. Therefore, the MAI scores for medications in our 
study ranged between 0 and 15. The comorbidity status of patients was also evaluated using 





Ethics approval was obtained from the Tasmanian Health and Medical Human Research Ethics 
Committee (H0016044).  
Statistical analyses 
Data were checked for normality of distribution via Shapiro-Wilk’s p-value of > 0.05 and visual 
inspection of histograms. Continuous variables were reported as mean ± SD for parametric data 
or median (interquartile range [IQR]) for non-parametric data. Frequency (percentage) was 
used to report proportions for categorical variables.  
Patients were included in the medication review group when there were documented 
recommendations/notes given by pharmacists during hospitalisation. A chi-square test was 
used to compare categorical variables in people with or without medication review, whereas 
the independent-samples t test and Mann-Whitney U test were applied for continuous variables. 
For the medication review group, the baseline MAI scores were compared with the scores after 
medication review, (a) assuming all recommendations were accepted and (b) after outcome 
(acceptance or non-acceptance) of recommendations by physicians, using Wilcoxon signed 
ranks test. Similarly, the MAI scores at hospital admission and discharge were compared using 
the same test for the patients without medication review. Finally, in people with (i) at least one 
recommendation and (ii) all recommendations accepted by physicians, the MAI before 
medication review was compared with the one after medication review. Analyses were 
performed using SPSS, version 23 (Armonk, NY: IBM Corp.). 
Results  
A total of 204 patients consecutively admitted to the study hospital for medical (75%) and 
surgical reasons (25%) were retrospectively categorised into two groups as follows: medication 
review (n=95) and no medication review (n=109). The baseline characteristics of patients are 
presented in Table 1. There were no significant differences between the two groups.  
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The impact of medication review on medication appropriateness 
In the medication review group, the median (IQR) baseline MAI score of patients declined 
after medication review (7 [3-12] to 5 [2-10]; p<0.001) and after the outcome of 
recommendations (7 [3-12] to 6 [2-10]; p<0.01). The median MAI score also decreased 
significantly from admission to discharge (6 [3-11] to 5 [2-9]; p<0.001) in patients with no 
medication review. Table 2 
Of patients who had received medication review by pharmacists, at least one recommendation 
was accepted by physicians in almost half of the patients (47%). In patients with at least one 
recommendation accepted, a marked improvement in medication appropriateness – a 3-unit 
cumulative decline in median MAI score, (7 to 4; p<0.01) – was observed. Similarly, in people 
whose recommendations were all accepted, a median MAI reduction of 4 units was observed 
(7 to 3; p<0.05). Table 2  
Characteristics of recommendations given by pharmacists 
Table 3 shows the type of recommendations given by pharmacists and the medications 
implicated in drug-related problems. Nearly half of the recommendations given by pharmacists 
had an impact on MAI (46%). Dosage adjustment (51%) and medication cessation (38%) were 
the most common recommendation types with an impact on MAI. These recommendations 
were also more likely to be accepted by physicians; 92% of medication cessation and 63% of 
dosage adjustment recommendations were accepted. Specifically, dosage adjustment 
recommendations related to anticoagulant medications had a high acceptance rate by 
physicians (8 out of 11 recommendations). Similarly, among recommendations for medication 
cessation, medications advised to be avoided in older people (e.g. benzodiazepines and 
amiodarone) and those that need adjustment or avoidance in severe renal impairment (e.g. 
dabigatran and spironolactone) were among recommendations often accepted by physicians.  
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In contrast, dosage adjustment recommendations related to metformin, allopurinol, 
moxonidine, and epleronone were among recommendations that were not accepted by 
physicians. In particular, only half of the recommendations for metformin dose adjustment 
were accepted (3 out of 6). The recommendations that were not accepted by physicians were 
all made in patients with eGFR between 30 and 60mL/min/1.73m2. Moreover, although they 
had no impact on MAI, more than half of recommendations related to initiation of therapy were 
not accepted by physicians (55%). These included initiations of prophylaxis for venous 
thromboembolism and deep vein thrombosis, addition of antihypertensives, such as ramipril 
and atenolol, and supplementation of vitamin D. 
Discussion  
Almost half of the older adults with CKD had a pharmacist-conducted medication review 
during their hospital stay. People who had  medication review by pharmacists were not 
different from those with no medication review in terms of important patient characteristics. In 
both groups, after hospitalisation, an improvement in medication appropriateness, as assessed 
with the MAI, was observed. Reassuringly, this demonstrates that hospital admission alone and 
the associated clinical care improved medication appropriateness. Although not significantly 
different, there was a trend indicating that people with pharmacist-conducted medication 
review had greater improvement. Importantly, a considerable median reduction in MAI was 
observed in patients with at least one recommendation accepted by physicians. The reduction 
was even higher in patients whose recommendations were fully accepted.  
The observed reduction in MAI after physicians’ acceptance of pharmacist recommendations 
was comparable to other hospital studies that evaluated medication appropriateness in older 
adults using the MAI.14,23 However, this reduction is much lower than that observed from 
medication review studies in community settings.12,13 This could be because, in accordance 
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with the eligibility criteria for medication management reviews,24 patients targeted by HMRs 
are typically those on more medications. Therefore, these patients may have an increased risk 
of medication-related problems necessitating a substantial review by pharmacists, leading to a 
marked reduction in MAI.  
The improvement in medication appropriateness, especially after acceptance of pharmacists’ 
recommendations by physicians, is indicative of the positive role pharmacists can play in 
potentially reducing adverse drug events. Pharmacist-led medication review has been linked to 
a reduction in medication-related hospitalisations and improved healthcare service 
utilisation.25,26 Nevertheless, more than half of the patients included in this study did not receive 
medication review by pharmacists. Implementing a standard clinical pharmacy service for all 
hospitalised patients may result in a better improvement in medication appropriateness.  
The most common recommendations by pharmacists with an impact on MAI were dosage 
adjustment and medication cessation. Other studies also reported medication cessation as the 
most common type of recommendation.12,13,27 The recommendations related to dosage 
adjustment in our study, while not surprising, also indicate pharmacists’ recognition of the poor 
renal function in these patients. Despite the need to recognise medications that need dosage 
adjustment in renal impairment, CKD patients have complex regimens that require a tho ough 
medication appropriateness assessment. For example, patients will benefit if pharmacists assess 
other important factors, such as drug-drug and drug-disease interactions. The recommendations 
given by pharmacists were accepted in nearly half of patients with medication review (47%). 
Previous studies have reported acceptance rates ranging between 45% and 69%, depending on 
the study setting and population targeted.12,13,23,27  
It was interesting to note that pharmacists’ recommendations were perhaps less likely to be 
accepted when based on evidence that was limited or changing; for instance, the risk of lactic 
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acidosis in patients treated with metformin and the need for dosage reduction in mild to 
moderate CKD has been seemingly overemphasised in the past.28,29  
Limitations 
The relatively small number of patients from a single site limited the statistical power to show 
significant differences and may have influenced the generalisability of the study. Despite the 
use of various explicit instructions, applying the MAI requires clinical judgment from the 
evaluator, which could pose a concern of reliability. However, the fact that the rating was 
performed by the same investigator had an advantage of avoiding potential inconsistencies. 
The validity of the MAI without the two subcomponents, ‘practicality of instructions’ and 
‘expense’, has not been investigated. Nevertheless, the individual components of the MAI were 
found to be valid and reliable.30 As a retrospective study, the MAI was evaluated based on 
secondary data at baseline and after medication review by pharmacists. Therefore, the 
pharmacists were not trained on how to use MAI and they were most likely not using this tool 
during the medication review. Further, we relied on information that was documented in the 
medical progress notes to examine the impact of medication review; it is possible we may have 
missed other recommendations because of poor documentation or because they were given 
verbally to physicians. Finally, we did not fully evaluate the evidence base and clinical 
rationale for each of the pharmacists’ recommendations but suspect that the uptake of 
recommendations and the improvement in medication appropriateness were greatest when 
these were strongest.  
Conclusion  
This study demonstrates that medication review by pharmacists, especially upon acceptance by 
physicians, can improve medication appropriateness in older hospitalised adults with CKD. 
Future studies should investigate if the pharmacist-led improvement in medication 
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appropriateness translates to positive clinical outcomes in these patients. Moreover, it is 
important to investigate the quality of recommendations given by pharmacists and the reasons 
for non-acceptance of some of the recommendations by physicians. 
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Table 1. Baseline characteristics of patients with and without pharmacist medication 
review 
 
Abbreviations: CCI, Charlson’s comorbidity index; eGFR, estimated glomerular filtration rate; ICD-10, 
International Classification of Diseases (tenth edition); IQR, interquartile range; MAI, Medication 















Age, years, mean (SD) 84 (8) 82 (10) 0.564 
Male gender, n (%) 55 (58) 70 (64)  0.416 
Serum creatinine, µmol/L, median (IQR) 132 (113-160) 136 (116-164) 0.638 
eGFR, mL/min/1.73m2, mean (SD) 37 (10) 37.2 (9.9) 0.828 
CCI, median (IQR) 4 (3-5) 4 (3-5) 0.747 
Length of hospitalisation, days 5 (3-9) 4 (2-7) 0.109 
Admission medications, mean (SD) 10 (4) 10 (4) 0.660 
Discharge medications, mean (SD) 11 (4) 10 (4) 0.116 
Admission MAI, median (IQR) 7 (3-12) 6 (3-11) 0.633 
Discharge MAI, median (IQR) 6 (2-10) 5 (2-9) 0.749 
Causes of hospitalisation (ICD-10 codes), n (%) 
Circulatory  40 (42) 44 (40)  
External causes and their 
consequences (falls and fractures) 
15 (16) 
 
14 (13)  
Mental and behavioural 7 (7.4) 0  
Infections  7 (7.4) 14 (13)  
Digestive  4 (4.3) 5 (4.6)  
Nervous system  2 (2) 5 (4.6)  




Table 2. The change in MAI scores in people with and without medication review and in 
patients whose recommendations were accepted by physicians 
 ¥Wilcoxon Signed Rank Test  
aMAI was measured assuming all recommendations by pharmacists were accepted  















Median MAI (IQR) p value¥ 
People with no medication review (n=109) 
At hospital admission  6 (3-11)  
At hospital discharge  5 (2-9) <0.001 
People with medication review (n=95) 
Before review  7 (3-12)  
After reviewa 5 (2-10) <0.001 
After outcome of recommendationsb 6 (2-10)   0.001 
People with at least one recommendation accepted (n=47) 
Before review 7 (3-14)  
After outcome of recommendations 4 (2-11) 0.004 
People with all recommendations accepted (n=19) 
Before review 7 (2-12)  
After outcome of recommendations 3 (1-8) 0.032 
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       Table 3. Type of recommendations given by pharmacists and medications implicated 































                   
Abbreviation: MAI, Medication Appropriateness Index 
Total recommendations (N=141) N  Medications implicated 
Recommendations with an impact on MAI (n=65) 
Dose adjustment 33  Atorvastatin, apixaban, allopurinol, enoxaparin, 
prednisolone, epleronone, metformin, pregabalin, 
moxonidine, rivaroxaban, gliclazide, furosemide, 
lercanidipine, propantheline, warfarin 
Cessation of medications 25  Digoxin, pregabalin, irbesartan, simvastatin, 
lercanidipine, tramadol, prednisolone, ramipril, 
indapamide, temazepam, aspirin, oxybutynin, 
travoprost, diazepam, mirtazapine, prazosin, 
atorvastatin, amiodarone, spironolactone, 
furosemide, potassium, dabigatran 
Drug-drug/-disease interaction 7  Atorvastatin, apixaban, diltiazem, irbesartan,  
moclobemide, moxonidine, pseudoephedrine,  
tramadol, spironolactone 
Drug change 5  Dabigatran, felodipine, perindopril, ranitidine 
Recommendations with no impact on MAI (n=76) 
Initiation of medications  18  Beta blockers, ramipril, dual antiplatelet therapy, 
iron, flunitrazepam, metformin, vitamin D, 
enoxaparin, magnesium, warfarin, esomeprazole 
Monitoring patients based on laboratory parameters,  
particularly renal function 
34 Enoxaparin, epleronone,  isosorbide mononitrate, 
gliclazide, pregabalin, moxonidine, lercanidipine, 
furosemide, ramipril, warfarin 
Medication adherence  15 Aspirin,  bisoprolol,  ezetimibe, iron,  isosorbide 
mononitrate, metoprolol, oxybutynin, simvastatin, 
travatan 
Others  4 Carvedilol, rivaroxaban, spironolactone 
